Stable solid compositions have a first carrier and an adsorbate having at least one active component, such as, a vitamin D derivative and a hydrophobic stabilizer thereof, wherein the first carrier is a calcium phosphate or derivatives thereof having a solubility in water lower than 0.1 wt % at room temperature.

Stable solid compositions have a first carrier and an adsorbate having at least one active component, such as, a vitamin D derivative and a hydrophobic stabilizer thereof, wherein the first carrier is a calcium phosphate or derivatives thereof having a solubility in water lower than 0.1 wt % at room temperature.

This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands. The method of administering the composition of the present invention consisting essentially of omega-3 fatty acids may further comprise (1) the steps of taking a baseline measurement of tear break up time of the mammal prior to administering the composition and taking a second measurement of tear break up time of the treated mammal after administration of the composition to evaluate the improvement in tear break up time of the mammal as compared to the corresponding baseline measurement, (2) the steps of taking a baseline measurement of tear osmolarity of the mammal prior to administering the composition and taking a second measurement of tear osmolarity of the mammal after administration of the composition to evaluate the reduction of tear osmolarity of the mammal as compared to the corresponding baseline measurement and/or (3) the steps of taking a baseline measurement of the quality of tears of the mammal prior to administering the composition and taking a second measurement of the quality of tears of the mammal after administration of the composition to evaluate the improvement in the quality of tears of the mammal as compared to the corresponding baseline measurement.

This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands. The method of administering the composition of the present invention consisting essentially of omega-3 fatty acids may further comprise (1) the steps of taking a baseline measurement of tear break up time of the mammal prior to administering the composition and taking a second measurement of tear break up time of the treated mammal after administration of the composition to evaluate the improvement in tear break up time of the mammal as compared to the corresponding baseline measurement, (2) the steps of taking a baseline measurement of tear osmolarity of the mammal prior to administering the composition and taking a second measurement of tear osmolarity of the mammal after administration of the composition to evaluate the reduction of tear osmolarity of the mammal as compared to the corresponding baseline measurement and/or (3) the steps of taking a baseline measurement of the quality of tears of the mammal prior to administering the composition and taking a second measurement of the quality of tears of the mammal after administration of the composition to evaluate the improvement in the quality of tears of the mammal as compared to the corresponding baseline measurement.

The invention encompasses compositions and methods for effectively treating and/or preventing diabetes and/or obesity. This is accomplished by totally addressing the multiple mechanisms that lead to such conditions. The invention includes compositions comprising a combination of agents that effectively suppress, regulate or interfere with the various biochemical processes and mechanisms that lead to diabetes and obesity. The inventive compositions used for administration to human and other mammalian subjects comprise (1) at least one agent capable of modulating expression and/or activity of one or more of peroxisome activated protein receptor gamma (PPAR-γ), CAAT/enhancer binding protein-α (C/EBPα) and Sterol Regulatory Element-Binding Protein (SREBP-1); (2) at least one agent capable of activating Wnt/β-catenin pathway; (3) at least one agent capable of activating the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway; (4) at least one agent that inhibits the activity of pro-oxidants including reactive nitrogen species and reactive oxygen species (ROS); (5) at least one agent that suppresses one or more of inflammatory mediators including interleukins IL-1α, IL-1β, IL-6, NF-κB, TNF-α, matrix metalloproteinases (MMPs) and prostaglandin E2 (PGE2); (6) at least one agent capable of enhancing glucose transporter (GLUT4) and/or inhibiting glucose transporter GLUT2; (7) at least one agent that induces the expression of and/or activates adiponectin and (8) at least one agent that induces the expression of and/or activates sirtuin (SIRT1). The active agents for use herein are natural materials such as phytonutrients, vitamins and minerals. Compositions with combinations of such natural agents have the ability to prevent, reduce or treat diabetes and obesity by (a) clearing glucose and fatty acids from blood, (b) reducing the number of adipose cells and fat storage, (c) interfering with fat, glucose, and cholesterol biosynthesis, and (d) promoting fat and glucose oxidation. Since the present compositions are aimed toward normalizing metabolism and energy expenditure and managing oxidative stress and inflammation, they are also beneficial in relation to physical activity, in particular performance, endurance, fatigue and recovery during intensive and continuous exercise/exertion.

The invention encompasses compositions and methods for effectively treating and/or preventing diabetes and/or obesity. This is accomplished by totally addressing the multiple mechanisms that lead to such conditions. The invention includes compositions comprising a combination of agents that effectively suppress, regulate or interfere with the various biochemical processes and mechanisms that lead to diabetes and obesity. The inventive compositions used for administration to human and other mammalian subjects comprise (1) at least one agent capable of modulating expression and/or activity of one or more of peroxisome activated protein receptor gamma (PPAR-γ), CAAT/enhancer binding protein-α (C/EBPα) and Sterol Regulatory Element-Binding Protein (SREBP-1); (2) at least one agent capable of activating Wnt/β-catenin pathway; (3) at least one agent capable of activating the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway; (4) at least one agent that inhibits the activity of pro-oxidants including reactive nitrogen species and reactive oxygen species (ROS); (5) at least one agent that suppresses one or more of inflammatory mediators including interleukins IL-1α, IL-1β, IL-6, NF-κB, TNF-α, matrix metalloproteinases (MMPs) and prostaglandin E2 (PGE2); (6) at least one agent capable of enhancing glucose transporter (GLUT4) and/or inhibiting glucose transporter GLUT2; (7) at least one agent that induces the expression of and/or activates adiponectin and (8) at least one agent that induces the expression of and/or activates sirtuin (SIRT1). The active agents for use herein are natural materials such as phytonutrients, vitamins and minerals. Compositions with combinations of such natural agents have the ability to prevent, reduce or treat diabetes and obesity by (a) clearing glucose and fatty acids from blood, (b) reducing the number of adipose cells and fat storage, (c) interfering with fat, glucose, and cholesterol biosynthesis, and (d) promoting fat and glucose oxidation. Since the present compositions are aimed toward normalizing metabolism and energy expenditure and managing oxidative stress and inflammation, they are also beneficial in relation to physical activity, in particular performance, endurance, fatigue and recovery during intensive and continuous exercise/exertion.

A compound composition for improving bone health and preparation and application thereof are provided. The compound composition is prepared by combining a traditional Chinese medicine extract with chicken cartilage collagen, magnesium, vitamin K2 and vitamin D3. The compound composition overcomes the food safety risk of the existing osteoporosis preventive drugs by adding the traditional Chinese medicine extract for improving osteoporosis and promoting bone health. And the compound composition disclosed can be used as a dietary supplement or health food raw material for preventing or treating osteoporosis. Therefore, the compound composition disclosed is suitable for promotion and application.

A compound composition for improving bone health and preparation and application thereof are provided. The compound composition is prepared by combining a traditional Chinese medicine extract with chicken cartilage collagen, magnesium, vitamin K2 and vitamin D3. The compound composition overcomes the food safety risk of the existing osteoporosis preventive drugs by adding the traditional Chinese medicine extract for improving osteoporosis and promoting bone health. And the compound composition disclosed can be used as a dietary supplement or health food raw material for preventing or treating osteoporosis. Therefore, the compound composition disclosed is suitable for promotion and application.

This application pertains generally to nutritional supplements comprising organic nutrients for consumption by a mammalian subject that supports and protects the immune system in a synergistic and complex way.

This application pertains generally to nutritional supplements comprising organic nutrients for consumption by a mammalian subject that supports and protects the immune system in a synergistic and complex way.